Immutep (IMMP)
NASDAQ:IMMP
Top Page
Immutep
(NASDAQ:IMMP)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.30
▼(-85.34% Downside)
Action:UpgradedDate:03/18/26
The score is primarily held down by weak financial performance (ongoing losses and negative cash flows) and bearish technical momentum (very low RSI/Stochastic and negative MACD). Valuation is also constrained by a negative P/E that reflects unprofitability and no dividend support.
Positive Factors
Partnership with Dr. Reddy’s strengthens cash position
The Dr. Reddy’s licensing deal delivered a meaningful upfront payment and milestone upside while preserving key territorial and manufacturing rights. This durable funding reduces near-term financing pressure, extends the company’s runway into 2027, and aligns partner incentives to advance efti without immediate equity dilution.
Negative Factors
Pivotal trial halted after futility review
Stopping a Phase III registrational study is a major structural setback for the lead oncology program. It materially reduces the likelihood of regulatory approval and future commercial royalties for efti, forces strategic reallocation of resources, and raises long-term uncertainty about the company’s pathway to commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership with Dr. Reddy’s strengthens cash position
The Dr. Reddy’s licensing deal delivered a meaningful upfront payment and milestone upside while preserving key territorial and manufacturing rights. This durable funding reduces near-term financing pressure, extends the company’s runway into 2027, and aligns partner incentives to advance efti without immediate equity dilution.
Read all positive factors
Immutep (IMMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$41.73M
Dividend YieldN/A
Average Volume (3M)2.42M
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue GrowthN/A
EPS Growth-17.16%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding147,372,130
10 Day Avg. Volume548,372
30 Day Avg. Volume2,420,017
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit-0.14
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$19.15M
Immutep Business Overview & Revenue Model
Company Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate...
How the Company Makes Money
Immutep is a clinical-stage biotech and does not primarily generate revenue from selling approved commercial products; its ability to generate income is largely tied to partnering and external funding mechanisms. Key ways the company makes (or see...
Immutep Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.92M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -74.78M | -56.37M | -37.70M | 1.44M | -1.89M | -13.37M |
| EBITDA | -81.38M | -62.88M | -44.54M | -39.57M | -31.87M | -17.77M |
| Net Income | -83.92M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 147.20M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 99.13M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.21M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 48.30M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 98.90M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -61.75M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -61.63M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | 58.95M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -208.44K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Technical Analysis
Negative
2.04
Price Trends
1.75
Negative
2.16
Negative
1.97
Negative
Market Momentum
-0.42
Negative
11.75
Positive
9.62
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Negative. The current price of 2.04 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 1.75, and above the 200-day MA of 1.97, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 11.75 is Positive, neither overbought nor oversold. The STOCH value of 9.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMP.
Immutep Risk Analysis
Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immutep Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $271.16M | -7.16 | -69.63% | ― | 158.54% | 66.90% | |
47 Neutral | $521.85M | -1.92 | -90.52% | ― | -34.92% | -43.26% | |
44 Neutral | $158.52M | -0.51 | 279.62% | ― | ― | ― | |
44 Neutral | $270.65M | -6.10 | -300.94% | ― | ― | ― | |
41 Neutral | $41.73M | ― | -69.20% | ― | ― | -17.16% |
* Healthcare Sector Average
IMMP
Immutep
0.31
-1.20
-79.60%
CLLS
Cellectis SA
4.28
2.82
193.15%
RNAC
Cartesian Therapeutics
5.93
-6.04
-50.46%
SLN
Silence Therapeutics
6.01
3.21
114.46%
LYEL
Lyell Immunopharma
24.80
15.62
170.15%
Immutep Corporate Events
Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
Mar 20, 2026
On March 19, 2026, Immutep reported positive progress from its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, in healthy participants. The company has completed the single ascending dose ph...
Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
Mar 16, 2026
On March 13, 2026, Immutep said an Independent Data Monitoring Committee recommended halting its TACTI-004 Phase III trial of eftilagimod alfa in first-line non-small cell lung cancer after a planned interim futility analysis. The company will sto...
Immutep Doubles Half-Year Loss as R&D Spend Rises Despite New Dr. Reddy’s Funding
Feb 26, 2026
On 25 February 2026, Immutep released its Appendix 4D half-year financial report for the period ended 31 December 2025, showing total revenue and other income up 6% to A$7.7 million, supported by A$4.1 million in new collaboration revenue from Dr....
Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
Feb 10, 2026
On February 6, 2026, Immutep announced it had reached 50% of target enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line advanced or metastatic non-small cell lung cancer, with 378 patients now enrolled worldwide. The tria...
Immutep Secures Dr. Reddy’s Licensing Deal and Reports Strong Q2 FY26 Clinical and Cash Progress
Jan 30, 2026
On 29 January 2026, Immutep reported its Q2 FY26 activities, highlighted by a strategic collaboration and exclusive licensing deal with Dr. Reddy’s Laboratories for the development and commercialisation of its lead immunotherapy eftilagimod ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.